Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06036121 | A Study of ADRX-0706 in Select Advanced Solid Tumors | active not recruiting | Phase 1 | 144 | Adcentrx TherapeuticsINDUSTRY | 2 | Aug 17, 2025 | clinicaltrials |
| NCT06487455 | A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors. | recruiting | Phase 1 | 170 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | Aug 17, 2025 | clinicaltrials |
| NCT05708924 |
| MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer |
| terminated |
| Phase 1 |
| 1 |
| Masonic Cancer Center, University of MinnesotaOTHER |
| 1 |
| Aug 14, 2025 |
| clinicaltrials |
| NCT05906862 | AMT-253 in Patients With Selected Advanced Solid Tumours | recruiting | Phase 1 | 54 | Multitude Therapeutics (Australia) Pty LtdINDUSTRY | 1 | Aug 14, 2025 | clinicaltrials |
| NCT07121829 | Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors | terminated | Phase 1 | 44 | Day One Biopharmaceuticals, Inc.INDUSTRY | 2 | Aug 14, 2025 | clinicaltrials |
| NCT07122063 | Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 266 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 1 | Aug 14, 2025 | clinicaltrials |
| NCT05717348 | A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours | active not recruiting | Phase 1 | 120 | Elpiscience (Suzhou) Biopharma, Ltd.INDUSTRY | 1 | Aug 13, 2025 | clinicaltrials |
| NCT06547957 | A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors | active not recruiting | Phase 1 | 55 | iTeos TherapeuticsINDUSTRY | 1 | Aug 13, 2025 | clinicaltrials |
| NCT03314935 | A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors | completed | Phase 1 / Phase 2 | 149 | Incyte CorporationINDUSTRY | 3 | Aug 12, 2025 | clinicaltrials |
| NCT05109650 | Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumour Patients | terminated | Phase 1 | 13 | Bio-Thera SolutionsINDUSTRY | 1 | Aug 12, 2025 | clinicaltrials |
| NCT07070349 | A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 48 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 12, 2025 | clinicaltrials |
| NCT03762447 | A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors | completed | Phase 1 | 138 | Incyte CorporationINDUSTRY | 5 | Aug 11, 2025 | clinicaltrials |
| NCT04487236 | Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors | completed | Phase 1 | 61 | Suzhou Zanrong Pharma LimitedINDUSTRY | 1 | Aug 11, 2025 | clinicaltrials |
| NCT05836948 | The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 174 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 11, 2025 | clinicaltrials |
| NCT05685472 | MEDI5752 in Japanese Patients With Advanced Solid Tumors. | completed | Phase 1 | 6 | AstraZenecaINDUSTRY | 1 | Aug 8, 2025 | clinicaltrials |
| NCT06375564 | Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression | recruiting | Phase 1 | 20 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT06480240 | A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 117 | OBI Pharma, IncINDUSTRY | 2 | Aug 8, 2025 | clinicaltrials |
| NCT07100249 | A Study of HDM2012 in Patients With Advanced Solid Tumor | recruiting | Phase 1 | 129 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 8, 2025 | clinicaltrials |
| NCT07110883 | A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 400 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 1 | Aug 8, 2025 | clinicaltrials |
| NCT02836600 | A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors | completed | Phase 1 | 11 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06231550 | A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors | completed | Phase 1 | 21 | FindCure Biosciences (ZhongShan) Co., Ltd.INDUSTRY | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07110363 | A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer | not yet recruiting | Phase 1 | 58 | Biotroy TherapeuticsINDUSTRY | 0 | Aug 7, 2025 | clinicaltrials |
| NCT04778839 | Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors. | recruiting | Phase 1 | 98 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07107178 | A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma | not yet recruiting | Phase 1 | 58 | Biotroy TherapeuticsINDUSTRY | 0 | Aug 6, 2025 | clinicaltrials |
| NCT02903914 | Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors | completed | Phase 1 | 260 | Incyte CorporationINDUSTRY | 4 | Aug 5, 2025 | clinicaltrials |
| NCT02628574 | Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab | completed | Phase 1 | 109 | Leap Therapeutics, Inc.INDUSTRY | 1 | Aug 3, 2025 | clinicaltrials |
| NCT03059823 | A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors | completed | Phase 1 | 325 | Incyte CorporationINDUSTRY | 16 | Aug 3, 2025 | clinicaltrials |
| NCT05718557 | Study of PYX-106 in Solid Tumors | active not recruiting | Phase 1 | 47 | Pyxis Oncology, IncINDUSTRY | 3 | Aug 3, 2025 | clinicaltrials |
| NCT06048367 | Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor(CNSI-Fe(II)) | completed | Phase 1 | 19 | Sichuan Enray Pharmaceutical Sciences CompanyOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT07101549 | Treating Nectin-4-positive Advanced Solid Tumors With R-Star001 (Nectin-4-CART-IL18) | not yet recruiting | Phase 1 | 25 | changjianhuaOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT03013218 | A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) | completed | Phase 1 | 174 | ALX Oncology Inc.INDUSTRY | 2 | Aug 1, 2025 | clinicaltrials |
| NCT06463340 | Study of SGR-3515 In Participants With Advanced Solid Tumors. | recruiting | Phase 1 | 52 | Schrödinger, Inc.INDUSTRY | 2 | Aug 1, 2025 | clinicaltrials |
| NCT07098052 | A Study of HDM2020 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 60 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 1, 2025 | clinicaltrials |
| NCT03729596 | MGC018 With or Without MGA012 in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 143 | MacroGenicsINDUSTRY | 4 | Jul 31, 2025 | clinicaltrials |
| NCT06484556 | T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor | recruiting | Phase 1 | 9 | Tao ZhangOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT02775292 | Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1(NYM) | completed | Phase 1 | 1 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT06105021 | Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 100 | Affini-T Therapeutics, Inc.INDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT07092748 | A Phase Ia/ Ib Study of HS387 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 110 | Zhejiang Hisun Pharmaceutical Co. Ltd.INDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT01309490 | Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients | terminated | Phase 1 / Phase 2 | 5 | Jewish General HospitalOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT02428712 | A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors | completed | Phase 1 / Phase 2 | 113 | Fore BiotherapeuticsINDUSTRY | 1 | Jul 29, 2025 | clinicaltrials |
| NCT04306900 | TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers | completed | Phase 1 | 185 | Trishula Therapeutics, Inc.INDUSTRY | 2 | Jul 29, 2025 | clinicaltrials |
| NCT06220838 | Study SC-101 in Subjects With Advanced Malignancies | recruiting | Phase 1 | 100 | Tianjin ConjuStar Biologics Co., Ltd.INDUSTRY | 1 | Jul 29, 2025 | clinicaltrials |
| NCT06710158 | Study of SC-102 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 120 | Tianjin ConjuStar Biologics Co., Ltd.INDUSTRY | 1 | Jul 29, 2025 | clinicaltrials |
| NCT05391022 | Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies | completed | Phase 1 | 35 | Constellation PharmaceuticalsINDUSTRY | 3 | Jul 28, 2025 | clinicaltrials |
| NCT07088588 | Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors | not yet recruiting | Phase 1 | 105 | Hangzhou SynRx Therapeutics Biomedical Technology Co., LtdINDUSTRY | 1 | Jul 28, 2025 | clinicaltrials |
| NCT05035745 | Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) | recruiting | Phase 1 / Phase 2 | 63 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05275777 | A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 66 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05491083 | Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer(ComPACT) | recruiting | Phase 1 / Phase 2 | 51 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT06208410 | A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 306 | Risen (Suzhou) Pharma Tech Co., Ltd.INDUSTRY | 1 | Jul 25, 2025 | clinicaltrials |
| NCT06428500 | QTX3046 in Patients With KRAS G12D Mutations | active not recruiting | Phase 1 | 240 | Quanta TherapeuticsINDUSTRY | 1 | Jul 25, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Aug 17, 2025source: clinicaltrials